Surgical Outcomes of Retroperitoneal Lymph Node Dissection for Growing Teratoma Syndrome in Testicular Cancer
Overview
Growing Teratoma Syndrome (GTS) occurs in up to 7.6% of non-seminomatous germ cell tumour (NSGCT) cases, characterized by enlarging masses despite normalized tumour markers. Retroperitoneal lymph node dissection (RPLND) remains the standard treatment, with variable operative times, complication rates, and generally favorable survival outcomes reported across 15 studies involving 156 patients.
Background
GTS is a rare clinical entity defined by growth of mature teratoma masses during or after chemotherapy in NSGCT patients, despite normalized serum tumour markers. It is predominantly located in the retroperitoneum and is resistant to chemotherapy and radiotherapy. The pathogenesis involves complex mechanisms including cellular differentiation and chemoresistance. Surgical resection via RPLND is the mainstay of management to prevent morbidity and potential malignant transformation.
Data Highlights
Parameter
Range/Value
Studies Reporting
Incidence of GTS in NSGCT
2.8% - 7.6%
2 studies
Median age at presentation
16 - 38 years
15 studies
Interval to RPLND
2 - 30 months
15 studies
Operative time (median)
160 - 432 minutes
4 studies
Estimated blood loss
225 - 2500 mL
5 studies
Adjunctive procedures required
10% - 100%
15 studies
Postoperative complication rate
12.5% - 44%
5 studies
Clavien-Dindo grade ≥ III complications
12.5% - 25%
5 studies
Disease-free survival at last follow-up
41.7% - 100%
14 studies
Overall survival at last follow-up
73.7% - 100%
15 studies
Key Findings
GTS incidence among NSGCT patients treated with chemotherapy ranges from 2.8% to 7.6%, predominantly affecting young males aged 16 to 38 years.
Mature teratoma tissue was confirmed histologically in 91.7% to 100% of RPLND specimens, with somatic-type malignant transformation occurring in approximately 7.7% to 8.3% of cases.
Median operative time for RPLND ranged widely from 160 to 432 minutes, with estimated blood loss between 225 mL and 2500 mL.
Adjunctive surgical procedures were frequently required, ranging from 10% to 100% of patients, reflecting the complexity of resections.
Postoperative complication rates varied from 12.5% to 44%, with serious complications (Clavien-Dindo grade ≥ III) occurring in up to 25% of cases.
Follow-up data showed disease-free survival between 41.7% and 100%, and overall survival from 73.7% to 100%, indicating generally favorable long-term outcomes after RPLND.
Clinical Implications
Clinicians should maintain a high index of suspicion for GTS in NSGCT patients presenting with enlarging masses despite normalized tumour markers. Early surgical intervention with RPLND is critical, as chemotherapy and radiotherapy are ineffective. Awareness of potential operative complexity and complication risks is essential for preoperative planning and patient counseling.
Conclusion
GTS represents a rare but important clinical challenge in testicular cancer management, with surgical resection via RPLND offering effective disease control. Despite variability in operative parameters and complication rates, long-term survival outcomes are generally favorable.
References
Logothetis et al. 1982 -- First description of Growing Teratoma Syndrome
